News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
483,303 Results
Type
Article (8046)
Company Profile (140)
Press Release (475213)
Multimedia
Podcasts (4)
Webinars (6)
Section
Business (166800)
Career Advice (307)
Deals (25747)
Drug Delivery (7)
Drug Development (52882)
Employer Resources (14)
FDA (9765)
Job Trends (8579)
News (238296)
Policy (17924)
Tag
2027 Biotech Bay Elite (1)
2027 Biotech Bay Standard (3)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (1)
Academia (484)
Accelerated approval (21)
ADA (18)
Adcomms (1)
Allergies (94)
Alliances (33176)
ALS (102)
Alzheimer's disease (966)
Antibody-drug conjugate (ADC) (256)
Approvals (10348)
Artificial intelligence (311)
ASCO (159)
Autoimmune disease (197)
Automation (28)
Bankruptcy (262)
Best Places to Work (6967)
BIO (36)
BIOSECURE Act (1)
Biosimilars (104)
Biotechnology (89)
Bladder cancer (132)
Brain cancer (28)
Breast cancer (501)
Cancer (3570)
Cardiovascular disease (214)
Career advice (248)
Career pathing (1)
CAR-T (169)
Celiac Disease (1)
Cell therapy (470)
Cervical cancer (34)
Clinical research (47758)
Collaboration (1210)
Commercialization (1)
Compensation (1393)
Complete response letters (33)
COVID-19 (753)
CRISPR (62)
C-suite (714)
Cystic fibrosis (84)
Data (5520)
Denatured (4)
Depression (101)
Dermatology (60)
Diabetes (336)
Diagnostics (4158)
Digital health (36)
Diversity (1)
Diversity, equity & inclusion (4)
Drug discovery (147)
Drug pricing (7)
Drug shortages (2)
Duchenne muscular dystrophy (159)
Earnings (73058)
Editorial (1)
Employer branding (2)
Employer resources (14)
Events (87482)
Executive appointments (686)
FDA (12302)
Fibrodysplasia Ossificans Progressiva (8)
Friedreich's ataxia (17)
Frontotemporal dementia (23)
Funding (896)
Gene editing (124)
Generative AI (9)
Gene therapy (312)
GLP-1 (288)
Government (949)
Grass and pollen (2)
Guidances (280)
Healthcare (9321)
Hematology (94)
HIV (52)
Huntington's disease (22)
IgA nephropathy (61)
Immunology and inflammation (97)
Immuno-oncology (55)
Indications (151)
Infectious disease (939)
Inflammatory bowel disease (125)
Inflation Reduction Act (4)
Influenza (83)
Intellectual property (247)
Interviews (42)
IPO (12381)
IRA (2)
Job creations (1969)
Job search strategy (237)
JPM (1)
Kidney cancer (16)
Layoffs (59)
Legal (5209)
Liver cancer (43)
Longevity (15)
Lung cancer (493)
Lymphoma (242)
Machine learning (27)
Management (3)
Manufacturing (520)
Marketing (7)
MASH (116)
Medical device (8637)
Medtech (8760)
Mergers & acquisitions (14361)
Metabolic disorders (692)
mRNA (50)
Multiple sclerosis (102)
NASH (4)
Neurodegenerative disease (213)
Neuropsychiatric disorders (38)
Neuroscience (1788)
NextGen: Class of 2026 (3156)
Non-profit (847)
Obesity (219)
Opinion (10)
Ovarian cancer (156)
Pain (169)
Pancreatic cancer (191)
Parkinson's disease (196)
Partnered (11)
Patents (458)
Patient recruitment (479)
Peanut (31)
People (41165)
Pharmaceutical (30)
Pharmacy benefit managers (8)
Phase 1 (15435)
Phase 2 (21326)
Phase 3 (14361)
Pipeline (6687)
Policy (18)
Postmarket research (1572)
Preclinical (6528)
Press Release (34)
Prostate cancer (187)
Psychedelics (7)
Radiopharmaceuticals (187)
Rare diseases (560)
Real estate (3021)
Recruiting (6)
Regulatory (14710)
Reports (16)
Research institute (579)
Resumes & cover letters (46)
Rett syndrome (39)
RNA editing (6)
RSV (47)
Schizophrenia (100)
Series A (149)
Series B (118)
Service/supplier (4)
Sickle cell disease (62)
Spinal muscular atrophy (87)
Sponsored (5)
Startups (2019)
Stomach cancer (3)
Supply chain (49)
Vaccines (311)
Venture capital (17)
Weight loss (72)
Women's health (75)
Date
Today (60)
Last 7 days (263)
Last 30 days (1102)
Last 365 days (19103)
2026 (10829)
2025 (19256)
2024 (22996)
2023 (26546)
2022 (34598)
2021 (37172)
2020 (33478)
2019 (23267)
2018 (17473)
2017 (18769)
2016 (17920)
2015 (24271)
2014 (21684)
2013 (18139)
2012 (20223)
2011 (20448)
2010 (20339)
Location
Africa (228)
Alabama (71)
Alaska (2)
Arizona (293)
Arkansas (11)
Asia (17864)
Australia (2093)
California (11543)
Canada (3045)
China (506)
Colorado (465)
Connecticut (392)
Delaware (204)
Europe (24593)
Florida (1718)
Georgia (364)
Hawaii (3)
Idaho (46)
Illinois (680)
India (42)
Indiana (308)
Iowa (13)
Japan (388)
Kansas (98)
Kentucky (30)
Louisiana (24)
Maine (25)
Maryland (1156)
Massachusetts (7600)
Michigan (299)
Minnesota (540)
Mississippi (4)
Missouri (78)
Montana (20)
Nebraska (11)
Nevada (112)
New Hampshire (60)
New Jersey (2544)
New Mexico (12)
New York (2739)
North Carolina (1231)
North Dakota (4)
Northern California (5749)
Ohio (284)
Oklahoma (14)
Oregon (14)
Pennsylvania (2193)
Puerto Rico (20)
Rhode Island (30)
South America (407)
South Carolina (75)
South Dakota (1)
Southern California (4788)
Tennessee (114)
Texas (1862)
United States (37570)
Utah (345)
Vermont (1)
Virginia (146)
Washington D.C. (38)
Washington State (896)
West Virginia (1)
Wisconsin (73)
483,303 Results for "ajinomoto althea inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
PCI Pharma Services to Acquire US-based Aseptic Fill-Finish CDMO Ajinomoto Althea
April 24, 2025
·
3 min read
Press Releases
Piramal Pharma Solutions and Ajinomoto Bio-Pharma Services Collaborate to Support ADC Development and Manufacturing
April 16, 2026
·
5 min read
Ajinomoto Co., Inc. Enhances StemFit iPS Cell Expansion Medium
Ajinomoto Co., Inc. launched a new version of its StemFit™ iPSC expansion medium.
March 26, 2024
·
3 min read
Press Releases
Successful Extension of Nucleic Acid Aptamer Pharmacokinetics in Joint Research by Ajinomoto Co., Inc. and RIBOMIC Inc.
May 7, 2025
·
3 min read
Deals
Ajinomoto Co., Inc. to Acquire Forge Biologics for $620 Million1
Ajinomoto Co., Inc. and Forge Biologics, announced that they have entered into a definitive agreement by which Ajinomoto Co., will acquire Forge, a leading manufacturer of genetic medicines, in an all-cash deal for $620 million.
November 13, 2023
·
4 min read
Ajinomoto Co. Launches Silicon Valley CVC HQ to Grow U.S. Investments, Adds New Portfolios
Ajinomoto Co., Inc., the Japan-based multinational corporation covering food, healthcare and electronic materials, and built on “AminoScience,” has expanded its corporate venture capital arm with new U.S. headquarters to grow its investments in U.S. and global companies.
February 13, 2024
·
2 min read
Biotech Beach
Ajinomoto Bio-Pharma Services Garners Six ‘CDMO Leadership Awards,’ Further Establishing Its Industry Excellence
Ajinomoto Bio-Pharma Services, a leading provider of biopharmaceutical contract development and manufacturing services, received CDMO Leadership Awards in all six categories - Capabilities, Compatibility, Expertise, Quality, Reliability, and Service for both the Overall and Big Pharma respondent groups.
March 12, 2024
·
2 min read
Business
Ajinomoto Bio-Pharma Services Announces Leadership Changes at US Facility
Ajinomoto Bio-Pharma Services today announced leadership changes at the company’s site in San Diego, effective immediately.
May 18, 2023
·
3 min read
Business
Ajinomoto Althea, Inc. Announces Additions to Management Team as it transforms into a global CDMO
Ajinomoto Althea, Inc. announced that Bert Barbosa and Darwin Richardson, MBA, have joined Althea as Vice President of Drug Product Manufacturing and Vice President of Compliance, respectively.
May 31, 2018
·
3 min read
Business
Ajinomoto and Exelixis Enter Into a License Agreement to Discover and Develop Novel Antibody-Drug Conjugates for the Treatment of Cancer
Ajinomoto Co., Inc. (“Ajinomoto Co.”) today announced a license agreement with Exelixis, Inc. (“Exelixis”) to incorporate AJICAP®, Ajinomoto Co.'s proprietary site-specific bioconjugation and linker technologies, in the development of certain of Exelixis’ antibody-drug conjugate (ADC) programs.
January 10, 2023
·
4 min read
1 of 48,331
Next
